ViaNautis Bio Ltd closes US$25m Series A financing

Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.

Recordbreaking BIO-Europe in Munich, but: back to 2019

The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already […]

Amyl Therapeutics bags �11m Series A extension

Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a �11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. <br />&nbsp;<br /><br […]

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics

Pierre Fabre Laboratories SA has extended its global partnership with&nbsp;Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.

Scotland boosts bio-based manufacturing with �75m fund

Biotech companies in Scotland�s thriving bio-based manufacturing have been invited to apply for up to �1m funding within the Launchpad programme.

BioInnovation Institute Boosts Six Life Science Companies

Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BII’s Venture House programme.

Read more

Majority of EU agri-council supports NGT deregulation

At a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.

Read more

New detection method for protein degraders

German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.

Read more

??Study: New breeding methods hardly contribute to climate protection

According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.

Read more